22 Dec Lavipharm share re-enters ATHEX Main Market
Peania, 22 December 2022 – As of Friday, 23 December 2022, the shares of Lavipharm S.A. will be traded again on the Main Market of the Athens Stock Exchange.
Following the completion of the share capital increase, the Listings and Market Operation Committee of the Athens Stock Exchange (ATHEX) approved the transfer of all Lavipharm shares to the Main Market. The ATHEX Main Market mainly addresses medium and big capitalisation companies with growth prospects, while providing accessibility to cross-border capital raising and shares’ participation in European indices.
The Chairman of the Board of Directors, Minas Tanes, commented that “this is a very important milestone for Lavipharm, and I am proud that its share is again traded on the Main Market. Together, we have faced and overcome many challenges. The Share Capital Increase enables us to lead Lavipharm into a new era of growth and development.”
Telemaque Lavidas, Executive Member of the BoD, noted that “our reintegration into the ATHEX Main Market marks a new page, in which my team and I believed deeply, as we worked hard to lay the foundation for the future. Our shareholders and all Lavipharm employees have awaited this day, and their faith has been vindicated. We are continuing our growth path dynamically, always with respect for our values and our commitment to the new strategy we have carefully designed. We are now writing a new chapter in Lavipharm’s long history, and today we are taking the first step. We are again crossing the threshold of the Main Market and preparing for even greater success.”
With a history of 111 years, Lavipharm is today an integrated pharmaceutical Group engaged in research, development, production, import, marketing and distribution in Greece, with a strong international activity.